Scarica l'app Stockscreener
2.72
1.09%
-0.03
C 4 Therapeutics Inc Borsa (CCCC) Ultime notizie
C4 Therapeutics Details MOMENTUM Phase 2 Start, Eyes Near-Term Decision on EGFR Program at Barclays Confab - Yahoo Finance
Are you looking for a top momentum pick? Why C4 Therapeutics, Inc. (CCCC) is a great choice - MSN
18 new PTC Therapeutics hires receive stock options, RSUs - Stock Titan
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
CCCC SEC FilingsC4 Therapeutics, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
C4 Therapeutics: Cemsidomide Progress Keeps The Long-Term Thesis Intact (NASDAQ:CCCC) - Seeking Alpha
C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data - Finviz
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Bitget
C4 Therapeutics announces inducement grant under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
C4 Therapeutics, Inc. to join Barclays global healthcare conference fireside chat - Traders Union
Why C4 Therapeutics Inc. stock is popular among millennials2026 Trading Volume Trends & Fast Moving Stock Trade Plans - Naître et grandir
C4 Therapeutics Maps Accelerated Approval Path for Myeloma Drug Cemsidomide at TD Cowen Conference - MarketBeat
Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Vera Therapeutics announces inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
Fulcrum Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Are You Looking for a Top Momentum Pick? Why C4 Therapeutics, Inc. (CCCC) is a Great Choice - Yahoo Finance
Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
CRISPR firm Intellia hands 16,500 RSUs to six new hires - Stock Titan
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Bicara Therapeutics Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Bitget
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Yahoo Finance
KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - PharmiWeb.com
C4 Therapeutics : Our Corporate Presentation (d54f12) - marketscreener.com
Intellia Therapeutics (NTLA) CSO awarded options and RSUs - Stock Titan
Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Bitget
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - marketscreener.com
CCCC Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
C4 Therapeutics (NASDAQ:CCCC) Upgraded to Hold at Wall Street Zen - MarketBeat
C4 Therapeutics (CCCC) Quarterly Loss Narrows To US$20.5m Challenging Persistent Bearish Narratives - simplywall.st
Barclays Raises Price Target on C4 Therapeutics (CCCC) to $7.00 - GuruFocus
Barclays raises C4 Therapeutics stock price target on trial progress By Investing.com - Investing.com South Africa
Barclays Maintains Overweight on C4 Therapeutics (CCCC) Feb 26, 2026 - Meyka
C4 Therapeutics (NASDAQ:CCCC) Issues Earnings Results, Beats Expectations By $0.25 EPS - MarketBeat
Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Barclays raises C4 Therapeutics stock price target on trial progress - Investing.com
C4 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights - Investing News Network
C4 Therapeutics, Inc. SEC 10-K Report - TradingView
C4 Therapeutics (CCCC) outlines TPD pipeline, losses and major partnerships - Stock Titan
C4 Therapeutics, Inc. posts fourth quarter and full year 2025 financial results - Traders Union
C4 Therapeutics (Nasdaq: CCCC) details 2025 loss and cash runway to 2028 - Stock Titan
C4 Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
C4 Therapeutics, Inc. (NASDAQ:CCCC) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
C4 Therapeutics (CCCC) Price Target Increased by 14.49% to 11.51 - Nasdaq
Brookline Raises C4 Therapeutics Price Target Amid Trial Confidence - StocksToTrade
Brookline’s Bold Move Boosts C4 Therapeutics Stock Prospects - timothysykes.com
Context Therapeutics (CNTX) awards 270,000 stock options to Chief Legal Officer - Stock Titan
Brookline Capital Raises Price Target for C4 Therapeutics (CCCC) to $30 | CCCC Stock News - GuruFocus
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma - Investing News Network
0.48%
1.21%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):